Glycosylphosphatidylinositol-specific phospholipase D in nonalcoholic fatty liver disease: A preliminary study

Naga Chalasani, Raj Vuppalanchi, Nandita S. Raikwar, Mark A. Deeg

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Context: Recent studies demonstrated that de novo lipogenesis is increased in patients with nonalcoholic fatty liver disease (NAFLD). Patients with NAFLD also have plasma lipid abnormalities. These lipid abnormalities may in part be related to insulin resistance, which is common in patients with NAFLD. Insulin resistance is associated with alterations in proteins involved in lipid metabolism including glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD), which is involved in triglyceride metabolism. Objective: The objective of the study was to determine whether alterations in serum and hepatic levels of GPI-PLD occur in patients with NAFLD. Design and Patients: We examined the following: 1) levels of serum GPI-PLD in nondiabetics with nonalcoholic steatohepatitis, compared with matched controls; 2) hepatic expression of GPI-PLD mRNA in patients with normal liver or NAFLD; and 3) effect of overexpressing GPI-PLD vs. β-galactosidase (control) on global gene expression in a human hepatoma cell line. Results: The serum levels of GPI-PLD were significantly higher in patients with nonalcoholic steatohepatitis than in matched controls (119 ± 24 vs.105 ± 15 μg/ml, P = 0.047). The hepatic expression of GPI-PLD mRNA was increased nearly 3-fold in NAFLD patients, compared with patients with normal liver (3.1 ± 2.6 vs. 1.1 ± 1.0 arbitrary units per microgram total RNA, P = 0.026). Finally, overexpressing GPI-PLD was associated with an increase in de novo lipogenesis genes. Conclusions: Patients with NAFLD have elevated serum levels and hepatic expression of GPI-PLD, and its overexpression in vitro is associated with increased expression of de novo lipogenesis genes. These results suggest that GPI-PLD may play a role in the pathogenesis of NAFLD and/or its metabolic features and warrants further investigation.

Original languageEnglish
Pages (from-to)2279-2285
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume91
Issue number6
DOIs
StatePublished - 2006

Fingerprint

glycoprotein phospholipase D
Liver
Lipogenesis
Serum
Insulin Resistance
Genes
Non-alcoholic Fatty Liver Disease
Galactosidases
Insulin
Lipids
Messenger RNA

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Glycosylphosphatidylinositol-specific phospholipase D in nonalcoholic fatty liver disease : A preliminary study. / Chalasani, Naga; Vuppalanchi, Raj; Raikwar, Nandita S.; Deeg, Mark A.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 91, No. 6, 2006, p. 2279-2285.

Research output: Contribution to journalArticle

@article{0f4a2374604044b59ba22266f86c2a52,
title = "Glycosylphosphatidylinositol-specific phospholipase D in nonalcoholic fatty liver disease: A preliminary study",
abstract = "Context: Recent studies demonstrated that de novo lipogenesis is increased in patients with nonalcoholic fatty liver disease (NAFLD). Patients with NAFLD also have plasma lipid abnormalities. These lipid abnormalities may in part be related to insulin resistance, which is common in patients with NAFLD. Insulin resistance is associated with alterations in proteins involved in lipid metabolism including glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD), which is involved in triglyceride metabolism. Objective: The objective of the study was to determine whether alterations in serum and hepatic levels of GPI-PLD occur in patients with NAFLD. Design and Patients: We examined the following: 1) levels of serum GPI-PLD in nondiabetics with nonalcoholic steatohepatitis, compared with matched controls; 2) hepatic expression of GPI-PLD mRNA in patients with normal liver or NAFLD; and 3) effect of overexpressing GPI-PLD vs. β-galactosidase (control) on global gene expression in a human hepatoma cell line. Results: The serum levels of GPI-PLD were significantly higher in patients with nonalcoholic steatohepatitis than in matched controls (119 ± 24 vs.105 ± 15 μg/ml, P = 0.047). The hepatic expression of GPI-PLD mRNA was increased nearly 3-fold in NAFLD patients, compared with patients with normal liver (3.1 ± 2.6 vs. 1.1 ± 1.0 arbitrary units per microgram total RNA, P = 0.026). Finally, overexpressing GPI-PLD was associated with an increase in de novo lipogenesis genes. Conclusions: Patients with NAFLD have elevated serum levels and hepatic expression of GPI-PLD, and its overexpression in vitro is associated with increased expression of de novo lipogenesis genes. These results suggest that GPI-PLD may play a role in the pathogenesis of NAFLD and/or its metabolic features and warrants further investigation.",
author = "Naga Chalasani and Raj Vuppalanchi and Raikwar, {Nandita S.} and Deeg, {Mark A.}",
year = "2006",
doi = "10.1210/jc.2006-0075",
language = "English",
volume = "91",
pages = "2279--2285",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Glycosylphosphatidylinositol-specific phospholipase D in nonalcoholic fatty liver disease

T2 - A preliminary study

AU - Chalasani, Naga

AU - Vuppalanchi, Raj

AU - Raikwar, Nandita S.

AU - Deeg, Mark A.

PY - 2006

Y1 - 2006

N2 - Context: Recent studies demonstrated that de novo lipogenesis is increased in patients with nonalcoholic fatty liver disease (NAFLD). Patients with NAFLD also have plasma lipid abnormalities. These lipid abnormalities may in part be related to insulin resistance, which is common in patients with NAFLD. Insulin resistance is associated with alterations in proteins involved in lipid metabolism including glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD), which is involved in triglyceride metabolism. Objective: The objective of the study was to determine whether alterations in serum and hepatic levels of GPI-PLD occur in patients with NAFLD. Design and Patients: We examined the following: 1) levels of serum GPI-PLD in nondiabetics with nonalcoholic steatohepatitis, compared with matched controls; 2) hepatic expression of GPI-PLD mRNA in patients with normal liver or NAFLD; and 3) effect of overexpressing GPI-PLD vs. β-galactosidase (control) on global gene expression in a human hepatoma cell line. Results: The serum levels of GPI-PLD were significantly higher in patients with nonalcoholic steatohepatitis than in matched controls (119 ± 24 vs.105 ± 15 μg/ml, P = 0.047). The hepatic expression of GPI-PLD mRNA was increased nearly 3-fold in NAFLD patients, compared with patients with normal liver (3.1 ± 2.6 vs. 1.1 ± 1.0 arbitrary units per microgram total RNA, P = 0.026). Finally, overexpressing GPI-PLD was associated with an increase in de novo lipogenesis genes. Conclusions: Patients with NAFLD have elevated serum levels and hepatic expression of GPI-PLD, and its overexpression in vitro is associated with increased expression of de novo lipogenesis genes. These results suggest that GPI-PLD may play a role in the pathogenesis of NAFLD and/or its metabolic features and warrants further investigation.

AB - Context: Recent studies demonstrated that de novo lipogenesis is increased in patients with nonalcoholic fatty liver disease (NAFLD). Patients with NAFLD also have plasma lipid abnormalities. These lipid abnormalities may in part be related to insulin resistance, which is common in patients with NAFLD. Insulin resistance is associated with alterations in proteins involved in lipid metabolism including glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD), which is involved in triglyceride metabolism. Objective: The objective of the study was to determine whether alterations in serum and hepatic levels of GPI-PLD occur in patients with NAFLD. Design and Patients: We examined the following: 1) levels of serum GPI-PLD in nondiabetics with nonalcoholic steatohepatitis, compared with matched controls; 2) hepatic expression of GPI-PLD mRNA in patients with normal liver or NAFLD; and 3) effect of overexpressing GPI-PLD vs. β-galactosidase (control) on global gene expression in a human hepatoma cell line. Results: The serum levels of GPI-PLD were significantly higher in patients with nonalcoholic steatohepatitis than in matched controls (119 ± 24 vs.105 ± 15 μg/ml, P = 0.047). The hepatic expression of GPI-PLD mRNA was increased nearly 3-fold in NAFLD patients, compared with patients with normal liver (3.1 ± 2.6 vs. 1.1 ± 1.0 arbitrary units per microgram total RNA, P = 0.026). Finally, overexpressing GPI-PLD was associated with an increase in de novo lipogenesis genes. Conclusions: Patients with NAFLD have elevated serum levels and hepatic expression of GPI-PLD, and its overexpression in vitro is associated with increased expression of de novo lipogenesis genes. These results suggest that GPI-PLD may play a role in the pathogenesis of NAFLD and/or its metabolic features and warrants further investigation.

UR - http://www.scopus.com/inward/record.url?scp=33744957268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744957268&partnerID=8YFLogxK

U2 - 10.1210/jc.2006-0075

DO - 10.1210/jc.2006-0075

M3 - Article

C2 - 16595594

AN - SCOPUS:33744957268

VL - 91

SP - 2279

EP - 2285

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -